2021
Brain opioid segments and striatal patterns of dopamine release induced by naloxone and morphine
Shokri‐Kojori E, Naganawa M, Ramchandani VA, Wong DF, Wang G, Volkow ND. Brain opioid segments and striatal patterns of dopamine release induced by naloxone and morphine. Human Brain Mapping 2021, 43: 1419-1430. PMID: 34873784, PMCID: PMC8837588, DOI: 10.1002/hbm.25733.Peer-Reviewed Original ResearchConceptsOpioid receptor availabilityStriatal DA releaseDA releaseOpioid receptorsReceptor availabilityDopamine releaseStriatal dopamine releaseOpioid use disorderBrain-wide distributionInverse associationHealthy controlsStriatal distributionClinical studiesStriatal patternUse disordersSubcortical regionsVentral striatumGray matter segmentsReceptorsNaloxoneMorphineStriatumDA targetsRelease patternRelease
2014
Evaluation of the agonist PET radioligand [11C]GR103545 to image kappa opioid receptor in humans: Kinetic model selection, test–retest reproducibility and receptor occupancy by the antagonist PF-04455242
Naganawa M, Jacobsen LK, Zheng MQ, Lin SF, Banerjee A, Byon W, Weinzimmer D, Tomasi G, Nabulsi N, Grimwood S, Badura LL, Carson RE, McCarthy TJ, Huang Y. Evaluation of the agonist PET radioligand [11C]GR103545 to image kappa opioid receptor in humans: Kinetic model selection, test–retest reproducibility and receptor occupancy by the antagonist PF-04455242. NeuroImage 2014, 99: 69-79. PMID: 24844744, PMCID: PMC4140089, DOI: 10.1016/j.neuroimage.2014.05.033.Peer-Reviewed Original ResearchConceptsKappa-opioid receptorsTest-retest reproducibilityTest-retest variabilityAbsolute test-retest variabilityPF-04455242Time-activity curvesIntra-class coefficientOpioid receptorsRegional time-activity curvesMetabolite-corrected arterial input functionHuman positron emission tomography studiesPositron emission tomography studySelective KOR antagonistEmission tomography studiesReceptor occupancy studiesSuitable reference regionHalf maximal inhibitory concentrationAgonist tracersRegional VTAgonist PET radioligandOral doseKOR antagonistsMaximal inhibitory concentrationOral administrationPreclinical models